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High performance liquid chromatography (HPLC) gained its unprecedented position 
among bioanalytical techniques due to its effectivity and versatility. If tuned properly, it can 
separate complex mixtures and can be used for qualitative and quantitative analysis 
simultaneously, usually within a short time. Reliability of the HPLC methods is proven by 
their validation performed according to accepted guidelines. 
Iron chelation is considered to be an effective concept of treatment of various 
pathologies – from iron overload disease to cancer or neurodegenerative disorders. To 
develop new chelators for these indications it is important to investigate their structure-
activity relationship, the fate of the drug in organism and its relationship to biological effects 
and toxicity etc. Modern analytical methods are essential tools for these studies. 
The first part of this work presents validated LC-UV and LC-MS methods for assay 
of aroylhydrazone iron chelators and related pro-drugs in biological materials. In the study, 
the structure-activity relationship in the group of the aroylhydrazones was examined. We 
proved that alkyl substitution of hydrogen in the vicinity of the hydrazone moiety is key in 
enhancing their chemical stability due to steric hindrance of the hydrazone bond. 
Additionally, utilising developed analytical methods, we proved in further 
experiments that: 1) an oxidation-activated prodrug BSIH is more stable in vitro and has 
better pharmacokinetic properties in vivo than its active form SIH, 2) BSIH is less toxic and 
protects cells from hydrogen peroxide induced damage, 3) BSIH decomposes to SIH but also 
to salicylaldehyde which augments the protective effect of the drug. 
The next study was focused on the prochelator BHAPI, based on aroylhydrazone 
with improved stability in plasma (compared to SIH) – HAPI. The study proved that 
the prochelator is equimolarly activated to HAPI and both BHAPI and its active form reduce 
  
the toxicity induced by catecholamines and their oxidative products. These results show 
the concept of boronated prodrugs to be a promising approach for development of new 
effective chelating therapeutics.  
The second part of this work deals with systematic assessment of metabolism and 
pharmacokinetics of the cardioprotective drug dexrazoxane (DEX) and its metabolite 
(ADR-925). A validated LC-MS method was utilised in this study to analyse samples from 
both in vitro and in vivo experiments. Recorded data were processed in population study. Our 
results show that the experimental model utilising rabbits for cardioprotection studies 
provides high similarity in pharmacokinetics to clinical models. This work challenges 
the hypothesis that the cardioprotective effect of DEX is caused by its iron chelating 
metabolite – ADR-925, which should hamper Fenton chemistry in the heart. In addition, 
the current data corroborate the modern theory that parent compound DEX may protect 
the heart from anthracycline induced cardiotoxicity via inhibition of topoisomerase 2β. 
This new hypothesis is also augmented by the last paper included in this dissertation. 
It is focused on a DEX analogue JR-311 (where one methyl group was replaced by an oxo- 
group). New LC-MS method was developed to investigate stability, metabolism and 
penetration to cardiomyocytes of JR-311. The study revealed that JR-311 is quickly 
hydrolysed to an ADR-925-like compound – which leads to a complete loss of its protective 
effect. This finding pointed at the need for significant modification of design of in vitro 
experiments.  The modified in vitro study showed that JR-311 interacts with TOP2B as well 
as it protects the heart cells from anthracycline induced damage. Study showed that 
the presented structural modification does not hamper the activity of JR-311, but future 
development should be focused on more stable DEX analogues. 
 
